Arvinas (ARVN) Assets Average (2018 - 2026)
Arvinas (ARVN) posted quarterly Assets Average of $682.7 million for Q1 2026, down 34.75% year-over-year from $1.0 billion in Q1 2025, and down 12.6% quarter-over-quarter from $781.1 million in Q4 2025.
Analysis
Arvinas (ARVN) Assets Average (2018 - 2026) Analysis & Trends
Arvinas' Assets Average history runs 9 years deep, the most recent figure standing at $682.7 million for Q1 2026.
- In Q1 2026, Assets Average fell 34.75% year-over-year to $682.7 million; the TTM figure through Mar 2026 stood at $682.7 million (down 34.75% YoY), while the FY2025 annual figure was $904.6 million, down 24.49% from the prior year.
- Assets Average for Q1 2026 stood at $682.7 million, down from $781.1 million in the prior quarter.
- The five-year high for Assets Average was $1.5 billion in Q1 2022, with the low at $682.7 million in Q1 2026.
- The 5-year median for Assets Average is $1.2 billion (2023), against an average of $1.1 billion.
- The sharpest annual moves came in 2022 and 2026: Assets Average jumped 119.41% in 2022, then sank 34.75% in 2026.
- Arvinas' Assets Average stood at $1.3 billion in 2022, then declined by 9.24% to $1.2 billion in 2023, then decreased by 4.42% to $1.1 billion in 2024, then plunged by 30.83% to $781.1 million in 2025, then decreased by 12.6% to $682.7 million in 2026.
- Business Quant data shows ARVN's Assets Average at $682.7 million in Q1 2026, $781.1 million in Q4 2025, and $876.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - | 661.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 661.30 Mn |
| Mar 31, 2026 | 682.70 Mn |
| Dec 31, 2025 | 781.10 Mn |
| Sep 30, 2025 | 876.80 Mn |
| Jun 30, 2025 | 955.20 Mn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.26 Bn |
| Dec 31, 2023 | 1.18 Bn |
| Sep 30, 2023 | 1.07 Bn |
| Jun 30, 2023 | 1.13 Bn |
| Mar 31, 2023 | 1.22 Bn |
| Dec 31, 2022 | 1.30 Bn |
| Sep 30, 2022 | 1.37 Bn |
| Jun 30, 2022 | 1.45 Bn |
| Mar 31, 2022 | 1.53 Bn |
| Dec 31, 2021 | 1.59 Bn |
| Sep 30, 2021 | 1.12 Bn |